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Abstract
Treatment with effective antibiotics is one important strategy for syphilis control in China. This study aimed to evaluate the prevalence of
azithromycin resistance to T. pallidum in China. A cross-sectional study was conducted among 391 patients with early syphilis recruited from
STD clinics in eight cities during October 2008 and October 2011. The swabs were obtained from the moist lesions of the participating
patients. A touchdown/nested PCR of the 23S ribosomal RNA (rRNA) gene was performed on DNA samples extracted from these
specimens. The presence or absence of the A2058G point mutation, conferring resistance to azithromycin, was determined by restriction
enzyme digestion analysis of the PCR amplicon by MboII. Two hundred and eleven patients with primary or secondary syphilis were found
to have T. pallidum DNA in their moist lesions by PCR assays. The A2058G mutation was present in 91.9% (194/211, 95% CI, 87.2–95.1%) of
these patients, with no signiﬁcant differences noted between patients from the eastern part (93.8%), southern part (88.6%) and northern
part (95.2%) of China (v2 = 2.303, p 0.316). Compared with patients who had not taken macrolides in previous years before study entry, the
patients who had taken the antibiotics had a signiﬁcantly higher prevalence of azithromycin resistance (97.0% vs. 62.5%), with an odds ratio
of 19.65 (95% CI, 5.77–66.93). It can be concluded that prevalence of azithromycin resistance is substantial in China and consequently that
the macrolides should not be used as a treatment option for early or incubating syphilis in China.
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Introduction
Syphilis, a chronic infectious disease caused by the spirochaete
Treponema pallidum and usually transmitted through sexual
contact or from mother to baby, remains a signiﬁcant public
health problem globally. The World Health Organization
(WHO) estimated that there were 11 million new cases of
syphilis worldwide in 2005, and the majority of them occurred
in developing countries [1]. Since the 1980s, this disease has
made a strong resurgence in China, exceeding that seen in
other countries. Recent data from national surveillance
systems have shown that the rate of syphilis has jumped from
6.1 cases per 100 000 people in 2001 to 32.0 per 100 000 in
2011 [2]. In several major cities such as Shanghai in China, it is
now the leading notiﬁable infectious disease.
Treatment with effective antibiotics is one important
strategy for syphilis control. Although single intramuscular
injection of 2.4 million units (MU) of penicillin G benzathine is
the recommended therapy for early syphilis, azithromycin has
been used as an alternative or the third-line therapy in patients
who are allergic to penicillin in some countries [3,4] because it
has the advantage of a single oral dose administration rather
than intramuscular injection, which allows patients to deliver
the therapy to their sexual partners, and outreach workers to
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deliver the therapy in high-risk population settings to improve
treatment coverage. A recently published systematic review on
the basis of three randomized controlled trials indicates no
statistically signiﬁcant difference between azithromycin and
penicillin G benzathine in relative effectiveness for treatment
of early syphilis [5]. Meanwhile, monitoring for the resistances
of T. pallidum strains to macrolide antibiotics and azithromycin
treatment failures in patients with syphilis has already attracted
widespread attention in many countries, including China. A
high prevalence of azithromycin-resistant strains and treat-
ment failure has been reported among 39 patients with
primary and secondary syphilis in Shanghai [6], while no
resistance was found among 211 clinical specimens from 136
patients with syphilis in Taiwan [7].
In this study, we aimed to investigate the prevalence of
azithromycin-resistant T. pallidum among patients with early
syphilis at sexually transmitted disease (STD) clinics in
geographically different areas in China.
Methods
Study areas and participants
The study was conducted in eight cities in the east (Nanjing),
south (Nanning, Guangzhou, Jiangmen, Fuzhou and Chengdu)
and north (Harbin and Tianjin) parts of China during October
2008 and October 2011. Geographical locations of the study
sites are shown in Figure 1. Criteria for participating in the
study included: being patients attending the STD clinics in the
study cities; having moist lesions (chancres or condyloma lata)
consistent with diagnosis of primary or secondary syphilis
according to the national diagnosis guidelines [6]; having not
received any antibiotics for current syphilis infection before
enrollment; and having ability to give an informed consent.
After signing an informed consent form, the eligible patients
were interviewed to obtain socio-demographic and clinical
data and then underwent a blood and moist lesion specimen
collection for serological and molecular biology tests. The
study protocols were reviewed and approved by the Medical
Ethics Committee of the Chinese Academy of Medical Sciences
Institute of Dermatology in Nanjing, China.
Clinical specimens
All participants were requested to provide serum specimens
for syphilis serological testing and swab specimens for
molecular evaluation of T. pallidum.
Venous blood samples were obtained from 391 patients
with early syphilis. Swabs were also taken from the moist
lesions of these patients. Swab specimens were stored in
sterile containers at 70°C until they were transported to the
National STD Reference Laboratory at the National Centre
for STD Control in Nanjing for molecular evaluation there.
Dark-ﬁeld microscopy and serological tests
Exudates from ulcerative lesions were collected onto a clean
microscopic slide by placing the exudate directly on the slide
and were immediately examined under the dark-ﬁeld micros-
copy by an experienced technician at the local STD clinics.
Serum samples from recruited patients were simultaneously
tested using a non-treponemal test (Toluidine Red Unheated
Serum Test (TRUST); Shanghai Rongsheng Biotech, Shanghai,
China) and a treponemal test (Treponema pallidum particle
agglutination (TPPA); Fujirebio, Tokyo, Japan). Those speci-
mens with reactive TRUST further underwent a quantitative
TRUST testing. All the serological tests for syphilis were
conducted in the local STD clinics.
Detection of azithromycin resistance
Extraction of DNA from clinical specimens was accomplished
using the Qiagen QIAamp® mini kit (Qiagen GmbH, Hilden,
Germany) according to the manufacturer’s instructions. The
PCR assay of the polA gene was performed based on a
previously reported method [8]. The presence or absence of
the A2058G point mutation, conferring resistance to azithro-
mycin, was determined by touchdown/nested polymerase
chain reaction ampliﬁcation (PCR) of the 23S ribosomal
RNA (rRNA) gene, followed by restriction-digestion analysis
of the amplicon by MboII, as has been described previously [9].
The DNA extraction and PCR detection was conducted in the
National STD Reference Laboratory.
Statistical analysis
All data from the interview and the laboratory results were
concurrently double-entered into a computer database using
EpiData Software (version 3.0) by independent researchFIG. 1. Geographical locations of the study sites in China.
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assistants, and databases were evaluated for congruency. The
percentage of patients with PCR positivity for syphilis was
calculated. The prevalence of azithromycin resistance, with
95% conﬁdence intervals (CIs), was measured. Associations
between categorical variables were determined by the v2 test
or the Fisher exact test. The Student t-test was used to
determine differences between continuous variables. Results
with p values of  0.05 were considered to be statistically
signiﬁcant. All statistical analysis was performed using the
Statistical Program for Social Sciences (SPSS, version 13.0; SPSS,
Chicago, IL, USA) software.
Results
During the study period, a total of 391 moist lesions were
collected from 391 patients with early (primary or secondary)
syphilis at the STD clinics in eight cities, consisting of 112
(28.6%) from eastern, 187 (47.8%) from southern and 92
(23.5%) from northern China. T. pallidum DNA was detected
by PCR in the genital swab specimens obtained from 60.9%
(238 of 391) patients, with higher yields in eastern parts
(76.8%) compared with southern (55.6%) or northern parts
(52.2%) (v2 = 17.00, p < 0.001). There was no signiﬁcant
difference between lesions from the patients with primary
(64.1%; 95% CI, 57.7–70.0%) and secondary syphilis (56.3%;
95%CI, 48.5–63.7%) (v2 = 2.109, p 0.146). Of the 238 PCR-
positive specimens, 211 (88.7%; 95% CI, 84.0–92.1%) were
successfully subjected to restriction-digestion analysis. Overall,
two hundred and eleven of the 391 patients with early syphilis
were positive by PCR, with an overall positive rate of 54.0%.
The demographic and behavioural characteristics, the
clinical and laboratory syphilis data and the HIV status for
the 211 patients who were ﬁnally included for analysis of the
resistance are summarized in Table 1. Speciﬁcally, out of the
211 patients ranging in age from 19.6 to 57.9 years (mean,
30.1 years), 161 (76.3%) were male and 50 (23.7%) had been
married. Of the 96 patients with known HIV status, one (1.0%)
was positive for HIV infection. Of the 136 patients who
reported sexual orientation, two (1.3%) were men who had
anal sex with other men. Of the 211 patients with syphilis, 140
(66.4%) were diagnosed with primary syphilis and 71 (33.6%)
with secondary syphilis. Of the 155 patients who were aware
of whether they had a history of exposure to macrolide
antibiotics, 128 (82.6%) reported use of the antibiotics.
The restriction-digestion analysis of the T. pallidum 23S
rRNA gene PCR amplicon showed that the A2058G mutation,
conferring resistance to azithromycin, was present in 91.9%
(194/211; 95% CI, 87.2–95.1%) of specimens with ampliﬁable
DNA from the study subjects, indicating no signiﬁcant
differences between the patients from the eastern part
(93.8%; 95% CI, 86.4–97.3%), southern part (88.6%; 95% CI,
80.3–93.7%) and northern part (95.2%; 95% CI, 84.2–98.7%) of
China (v2 = 2.303, p 0.316). Compared with patients who had
not taken macrolides in previous years before study entry, the
patients who had taken the antibiotics had a signiﬁcantly higher
prevalence of azithromycin resistance (97.0% vs. 62.5%). The
relative risk of having the mutation was 19.65 (95% CI, 5.77–
66.93; p < 0.001) for patients who had a history of exposure
to macrolide antibiotics, compared with those who had not
(Table 2).
Discussion
In the current study, we used molecular technology to detect
the 23 rRNA mutation, which is associated with azithromycin
resistance, in clinical specimens from patients with early
TABLE 1. Demographic, behavioural, clinical and laboratory
characteristics of patients whose specimens were positive by
PCR ampliﬁcation (n = 211)
Variable Total No.* Value
Demographic and behavioural ﬁndings
Median age (IQR, range), years 211 37, 29–44
Male sex, n (%, 95% CI) 211 161 (76.3, 70.1–81.5)
Married, n (%, 95% CI) 211 152 (72.0, 65.6–77.7)
High school or above education,
n (%, 95% CI)
211 119 (56.4, 49.6–62.9)
Female sex worker, n (%, 95% CI) 49 3 (6.1, 2.1–16.5)
Sex with female sex worker,
n (%, 95% CI)
117 84 (71.8, 63.0–79.1)
Anal sex with other man, n (%, 95% CI) 143 2 (1.4, 0.4–5.0)
Biomedical ﬁndings
Previous STD infection, n (%, 95% CI) 188 50 (26.6, 20.8–33.3_
Previous syphilis infection, n (%, 95% CI) 198 9 (4.5, 2.4–8.4)
Positive dark-ﬁeld microscope,
n (%, 95% CI)
155 95 (61.3, 53.4–68.6)
HIV infection, n (%, 95% CI) 96 1 (1.0, 0.2–5.7)
*Total number of patients who responded to this question or got this testing.
IQR, interquartile range; CI, conﬁdence interval.
TABLE 2. Macrolide resistance to T. pallidum by geograph-
ical area and history of macrolide use and STDs (n = 211)
Variable Number
Resistance
% (95% CI) OR p value
Geographical area
Eastern China 81 93.8 (86.4–97.3) —
Southern China 88 88.6 (80.3–93.7) 0.51 0.243
Northern China 42 95.2 (84.2–98.7) 1.31 0.749
Previous use of macrolides
Yes 135 97.0 (92.6–98.8) 19.65 <0.001
No 32 62.5 (45.2-77.1) —
Unknown 44 97.7 (88.2–99.6) 25.8 <0.001
History of STDs
Yes 50 90.0 (78.6–95.6) —
No 138 93.5 (88.1–96.5) 1.59 0.425
No response 23 95.7 (79.0–99.2) 2.44 0.427
CI, conﬁdence interval; OR, odds ratios; STD, sexually transmitted disease.
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syphilis, and evaluated prevalence of the resistance among this
population recruited from geographically different regions in
China. Previous studies have reported geographical variations
in resistance of azithromycin to T. pallidum, indicating a high
prevalence of resistance in many developed countries (e.g.
66.6% in London, UK, and 77.3% in San Francisco, USA)
[10,11], but such resistance was uncommon in some develop-
ing countries (e.g. 0% in three cities in Madagascar) [12]. The
prevalence in our study exceeds that found in the developed
countries [10,11]. There have been a few studies on preva-
lence of macrolide-resistant T. pallidum in Asia [6,7] although
the disease is more prevalent and the use (or sometimes
misuse) of antibiotics in medical practice is more common in
this area [13]. All of 38 patients with primary syphilis were
found to be infected with macrolide-resistant strains in
Shanghai [6] while none of 102 specimens from patients
mostly infected with early syphilis were found to be resistant
to azithromycin in Taiwan where macrolides are infrequently
used [7]. In our present study, we found a high prevalence of
azithromycin-resistant T. pallidum (91.9%) in multiple sites
located in eastern (93.8%), southern (88.6%) and northern
parts of China (95.2%), which is consistent with the ﬁndings in
Shanghai. These ﬁndings suggest that the macrolide-resistant
strains of T. pallidum have spread across the country in China,
although on-going surveillance over a wider geographical area
is still needed. Antibiotic selection pressure is thought to be an
important method of selecting for antibiotic resistance in
populations [14]. The Chinese are on average taking 10 times
as many antibiotics as other nations [15] because doctors
routinely hand out multiple doses of antibiotics for simple
maladies and the drugs were still easily obtainable over-the-
counter in some areas. Our ﬁndings of approximately 20-fold
higher prevalence of macrolide resistance among patients who
had taken the antibiotics further support the theory that
antibiotic selection has contributed to the increases in the
macrolide-resistance of T. pallidum strains.
Previous molecular studies indicate that the strain type
distribution of T. pallidum in the current study areas (predom-
inant type of 14d/f at 39%) [16] was different from that
reported in Shanghai, where 14f (83%) was largely predom-
inant [6], or that reported in Taiwan, where 14f/f (50%) was
predominant [7], suggesting that currently circulating T. palli-
dum strains in the study areas may be unrelated to those in
Shanghai and Taiwan. However, a recently published study
from a similar setting in Shanghai reported a predominant type
of 14d/f, corroborating our ﬁndings [17]. The widespread and
high prevalence of macrolide resistance among T. pallidum in
China probably reﬂects selective pressure due to wide use of
macrolides for other indications, rather than the increased
spread of a single mutant T. pallidum strain.
In our study, the percentages of patients with syphilis
(54.0%) that were PCR positive were comparable to studies of
patients with primary ulcers and secondary lesions in the US
[11], but higher than those with blood specimens [18] or
primary ulcerative swabs in South Africa [19].
There are some limitations to be addressed. First, although
the study contained a large number of patients recruited from
eight geographically different urban areas to evaluate the
prevalence of macrolide resistance in China, the situation in
other areas, particularly in rural and remote areas, may be
different, and the sample size in some areas is still relatively small.
Second, the data regarding sexual behaviour and previous use of
macrolides are subject to self-reporting bias and recall bias.
However, the prevalence of resistance has been universally high
regardless of sexual behaviour or previous macrolide use.
There is still a debate on whether to include azithromycin at
all as an alternate single-dose therapy for the treatment of early
syphilis [20]. British guidelines for the management of syphilis
include macrolide antibiotics as alternative treatments for
incubating and early disease [3], and American guidelines for
treatment of primary and secondary syphilis include azithro-
mycin as an alternative treatment only when treatment with
penicillin or doxycycline is not feasible [4]. A systematic review
by Bai and colleagues was recently published in the Cochrane
Database Systematic Review [5], concluding no statistically
signiﬁcant difference between azithromycin and penicillin G
benzathine in relative effectiveness for treatment of early
syphilis. However, penicillin is still an antibiotic widely used in
the treatment of syphilis in China. T. pallidum resistance to
penicillin has not been documented in China or other
countries, after more than six decades of its use for treatment
of syphilis.
Conclusions
Our ﬁndings and other available data from recent reports of
failure of azithromycin in the treatment of early syphilis in
China [21] support recommendations that macrolides should
not be used as a treatment option for early or incubating
syphilis in China.
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